Quantitative insights towards the design of potent deazaxanthine antagonists of adenosine 2B receptors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 4, 2014, Pages 590-598

  Paz, Odailson Santos ^a   Brito, Camila Carane Bitencourt ^b   Castilho, Marcelo Santos ^b,c  

^a DEPARTAMENTO DE CIÊNCIAS BIOLÓGICAS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Instituto Nacional de Ciência e Tecnologia em Biologia Estrutural e Bioimagem   (Brazil)

Author keywords

2D QSAR; 3D QSAR; AdoRA2b; CoMFA; HQSAR; Sickle cell disease

Indexed keywords

ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; DEAZAXANTHINE ANTAGONIST; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG DESIGN; DRUG POTENCY; HUMAN; MOLECULAR INTERACTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SICKLE CELL ANEMIA; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; SYNTHESIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, ADENOSINE A2B; XANTHINES;

EID: 84904333697     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2013.830113     Document Type: Article

References (49)

1. Fredholm BB, Arslan G, Halldner L, et al. Structure and function of adenosine receptors and their genes. Naunyn Schmiedeberg's Arch Pharmacol 2000;362:364-74.
2. Fredholm BB. Adenosine receptor as drug targets. Cell Res 2010; 316:1284-8.
3. Fernandez F, Caamano O, Nieto MI, et al. 1,3-Dialkyl-8-Nsubstituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-Affinity and structure-selectivity relationships. Bioorg Med Chem 2009;17: 3618-29.
4. Joseph TB, Kumar BVSS, Santhosh B, et al. Quantitative structure activity relationship and pharmacophore studies of adenosine receptor A2B inhibitors. Chem Biol Drug Des 2008;2:395-408.
5. Baraldi, PG, Tabrizi MA, Preti D, et al. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2b adenosine receptor antagonists. J Med Chem 2004;47:1434-47.
6. Gladwin MT. Adenosine receptor crossroads in sickle cell disease. Nat Med 2011;17:38-40.
7. Wen J, Jiang X, Dai Y, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J 2010;24:740-9.
8. Ryzhov S, Goldstein AE, Matafonov A, et al. Adenosine-Activated mast cells induce IgE synthesis by B lymphocytes: An A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. J Immunol 2004;172:7726-33.
9. Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med 2011;17:79-86.
10. Simo'es BP, Pieroni F, Barros GMN, et al. Consenso brasileiro em transplante De células-tronco hematopoéticas: Comite' De hemoglobinopatias. Rev Bras Hemat Hemot 2010;32:46-53.
11. World Health Organization [internet]. Switzerland: World Health Organization; 2011. Available from: Http://www.who.int/medio center/factsheets/fs308/en [last accessed 5 Jun 2013]
12. Beukers M, Meurs I, Ijzerman P. Structure-Affinity relationships of adenosine A2B receptor ligands. Med Res Rev 2006;26:667-98.
13. Katritch V, Kufareva I, Abagyan R. Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacology 2011;60:108-15.
14. Cheng F, Xu Z, Liu G, Tang, YE. Insights into binding modes of adenosine A2B antagonists with ligand-based and receptor-based methods. J Med Chem 2010;45:3459-71.
15. Ganzalez MP, Teran C, Teijeira M. Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we?. Med Res Rev 2008;28:329-71.
16. Carotti A, Cadavid MI, Centeno NB, et al. Design, synthesis, and structure-Activity relationships of 1-,3-,8-, and 9-substituted-9- deazaxanthines at the human A2B adenosine receptor. J Med Chem 2006;49:282-99.
17. Carotti A, Stefanachi A, Raviña E, et al. 8-Substituted-9-deazaxanthines as adenosine receptor ligands: Design, synthesis and structure-Affinity relationships at A2B. Eur J Med Chem 2004;39: 879-87.
18. Doddareddy MR, Lee YJ, Cho YS, et al. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists. Bioorg Med Chem 2004;12:3815-24.
19. Salum LB, Andricopulo AD. Fragment-based QSAR: Perspectives in drug design. Mol Drive 2009;13:277-85.
20. Tong W, Lowis DR, Perkins R, et al. Evaluation of quantitative structure-Activity relationship methods for large-scale prediction of chemical binding to the estrogen receptor. J Chem Inf Comput Sci 1998;8:669-77.
21. Vrtacnik M, Voda K. HQSAR and CoMFA approaches in predicting reactivity of halogenated compounds with hydroxyl radicals. Chemosphere 2003;2:1689-99.
22. Stefanachi A, Brea JM, Cadavid MI, et al. 1-, 3- And 8-substituted-9- deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor. Bioorg Med Chem 2008;6:2852-69.
23. TALETE, User Manual Dragon version 5.5; Copyright: Italy; 2007.
24. TALETE, User Manual Mobydigs version 1.0; Copyright: Italy; 2004.
25. Todeschini R, Consonni V, Maiocchi A. The K correlation index theory development and its application in chemometrics. Chemom Intell Lab Syst 1999;6:13-29.
26. Todeschini R, Consonni V, Mauri A, Pavan M. Detecting "bad" regression models: Multicriteria fitness functions in regression analysis. Anal Chim Acta 2004;515:199-208.
27. INFOMETRIX, Multivariate Data Analysis. Infometrix, Inc; 2008.
28. HQSAR Manual, St. Louis, MO: Tripos Inc.; 2010.
29. Jain AN. Ligand-based structural hypotheses for virtual screening. J Med Chem 2004;47:947-61.
30. Cramer RD, Patterson DE, Bunce JD. Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 1989;291:161-5.
31. Consonni V, Ballabio D, Todeschini R. Evaluation of model predictive ability by external validation techniques. J Chemom 2010;24:194-201.
32. Chirico N, Gramatica P. Real external predictivity of QSAR models: How to evaluate it?. Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J Chem Inf Model 2011;51:2320-35.
33. Bandeira FMGC, Santos MNN, Bezerra MA, et al. Triagem familiar para o gene H.B.B. S e detecça'o De novos casos De traço falciforme em Pernambuco. Rev Saúde Pública 2008;42:234-41.
34. Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa a neglected cause of early childhood mortality. Am J Prev Med 2011; 41:S398-405.
35. Thakur M, Chandan N. Molecular modeling coupled with computed aided drug design. Int J Res Pharm Biomed Sci 2012;3:114-17.
36. Bhattacharya P, Leonard JT, Roy K. Exploring 3D-QSAR of thiazole and thiadiazole derivatives as potent and selective human adenosine A3 receptor antagonists. J Mol Model 2005;11:516-24.
37. Golobocanini DD, Skrbic BD, Miljevic NR. Principal component analysis for soil contamination with PAHs. Chemometr Intell Lab 2004;72:219-23.
38. Thomas J, Roy K. On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 2006;25: 235-51.
39. Roy K, Leonard JT, Sengupta C. QSAR of adenosine receptor antagonists. Part 3: Exploring physicochemical requirements for selective binding of 1,2,4-triazolo[5,1-i]purine derivatives with human adenosine A3 receptor subtype. Bioorg Med Chem Lett 2004;14:3705-9.
40. Freitas HF, Castilho MS. 2D chemometrics analyses of tetrahydroquinoline and ethylenediamine derivatives with antimalarial activity. Med Chem 2012;8:252-65.
41. Freitas HF, Paz OS, Castilho MS. Estudos De QSAR 3D para um conjunto De inibidores De butirilcolinesterase humana. Quim Nova. Nova 2009;32:2114-21.
42. Golbraikh A, Tropsha A. Beware of q2! J Mol Graph Mod 2002;20:269-76.
43. Castilho MS, Guido RVC, Andricopulo AD. 2D quantitative structure-Activity relationship studies on a series of cholesteryl ester transfer protein inhibitors. Bioorg Med Chem 2007;15:6242-52.
44. Salum LB, Polikarpov I, Andricopulo AD. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies. J Mol Graphics Mod 2007;26:434-42.
45. Honorio KM, Garratt RC, Polikarpov I, Andricopulo AD. 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. J Mol Graphics Mod 2007;25:921-7.
46. Consonni V, Ballabio D, Todeschini R. Comments on the definition of the Q2 parameter for QSAR validation. J Chem Inf Model 2009; 49:1669-78.
47. Schuurmann G, Ebert RU, Chen J, et al. External validation and prediction employing the predictive squared correlation coefficient - test set activity mean vs training set activity mean. J Chem Inf Model 2008;48:2140-5.
48. Akamatsu M. Current sate and perspectives of 3D-QSAR. Curr Top Med Chem 2002;2:1381-94.
49. Gohlke H, Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew Chem Int Ed 2002;41:2644-76.